Preliminary clinical evidence shows that Lisaftoclax can overcome resistance to venetoclax in myeloid malignancies, with an overall response rate of 31.8% in this subgroup. The drug achieved an 80% overall response rate in newly diagnosed high-risk MDS/CMML patients with a strong safety profile. Ascentage Pharma presented these results at the ASH Annual Meeting, showcasing the potential of Lisaftoclax in treating venetoclax-resistant patients. The drug is currently under investigation in Phase III studies for multiple indications, including CLL/SLL, AML, and MDS. Lisaftoclax is a Bcl-2 selective inhibitor that holds promise in the clinical management of myeloid malignancies.

A Phase Ib/II study presented at ASH 2025 evaluated the efficacy and safety of Lisaftoclax in combination with azacitidine for patients with newly diagnosed or relapsed/refractory myeloid malignancies. The study included 103 patients with AML/MPAL and HR MDS/CMML, showing an overall response rate of 43.2% in R/R AML/MPAL and 80.0% in ND HR MDS/CMML. No dose-limiting toxicities were reported, with common grade ≥3 treatment-emergent adverse events including neutropenia and febrile neutropenia. The study demonstrated the potential of the combination regimen to offer a new treatment option for patients with AML/HR MDS.

Read more at GlobeNewswire: ASH 2025 | Ascentage Pharma Presents Encouraging Data from